68 results about "FAILURE KIDNEY" patented technology

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.

An extracorporeal circuit for removing toxins from the blood and plasma volume control in patients suffering from sepsis and renal failure. The extracorporeal circuit disclosed herein comprises a plasma filter, a toxin removal device and optionally a hemofilter that minimizes electrolyte and protein depletion from the treated plasma while effectively removing both free and protein-bound toxins. The toxin removal device comprises adsorbent materials selected from the group consisting of activated carbon, ion exchange resins and non-ionic exchange resins and the adsorbent materials are coated with albumin. Also provided are associated methods for treating patients suffering from sepsis and renal failure using the disclosed extracorporeal circuit and toxin removal device.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble p-selectin, protein NOV homolog, soluble epidermal growth factor receptor, netrin-4, haptoglobin, heat shock protein beta-1, alpha-1-antitrypsin, leukocyte elastase, soluble tumor necrosis factor receptor superfamily member 6, soluble tumor necrosis factor ligand superfamily member 6, soluble intercellular adhesion molecule 2, active caspase-3, and soluble platelet endothelial cell adhesion molecule as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C—X—C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin-1, C—C motif chemokine 22, C—C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.

The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.

The present invention relates to a method of predicting if a diabetes type 1 patient will suffer from one or more complications selected from cardiovascular complications, terminal renal failure, and death, the method including (a) determining the amount of GDF-15 in a sample of a diabetes type 1 patient; and (b) comparing the amount of GDF-15 determined in step (a) to a reference amount and establishing a prediction. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.

Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to ameliorate renal failure (e.g., improved diuretic effect and/or lowering blood urea nitrogen, proteinuria, and/or serum creatinine levels) in a subject as a result of having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using such compositions.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-X-C motif chemokines-1, -2, and -3 as diagnostic and prognostic biomarker assays in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses a full-automatic intelligent peritoneal dialysis instrument for renal failure, which comprises a PIC temperature weighing signal detection regulating unit, a PLC controlling arrangement, an intelligent IC card system, a peristaltic pump and a dislysate pipe-line system through interconnection, wherein the PIC temperature weighing signal detection regulating unit are connected with temperature sensors and weighing sensors, the PLC controlling arrangement is connected with a touch screen and an intelligent IC card system.

It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.

The present invention relates to a therapeutic agent for renal failure comprising, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also relates to a method of treatment of renal failure using the same.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Endothelin-1, Somatotropin, and Interleukin-13 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

The invention relates to a traditional Chinese medicine preparation for treating chronic renal failure and a preparation method. The invention aims to provide a traditional Chinese medicine preparation for treating chronic renal failure, which has obvious therapeutic effect, low cost, safety and reliability, good tolerance and high patient compliance. The traditional Chinese medicine preparation for treating chronic renal failure is prepared from raw materials comprising Astragalus mongholicus, epimedium herb, agilawood powder, roots of red-rooted salvia, prepared rhubarbs, red flowers and prepared sealwort. The traditional Chinese medicine preparation can regulate the metabolism functions of organisms, increase the exhaustion of the organisms for pathological products and reduce the retention of organic matter in bodies through the functions of replenishing vital essence, warming yang and eliminating turbid matter, thereby having the functions of protecting the organisms and strengthening kidney compensation. Compared with a method for treating by singly using Western medicine, the traditional Chinese medicine preparation has the characteristics of safe use, obvious effect of improving renal functions and promotion of toxin discharge and has an obvious function on delaying renal failures.

The invention discloses a composition for preventing and/or treating renal injury and renal failure. The composition is prepared from one or more of MG53 protein and a MG53 protein mutant, wherein theMG53 protein mutant is a structure that a serine site in a Coiled-coil structural domain of the MG53 protein is mutated as alanine, specifically one or more of MG53 S150A, MG 53 S189A, MG53 S211A. The invention further discloses a composition for preventing and/or treating renal injury and renal failure. The composition containing the MG53 protein and/or the mutant thereof utilizes recombinant human MG53 protein to prove that the MG53 has obvious preventing and/or treating effect for chronic ulcer in a drug for preventing and/or treating renal injury and renal failure, and is of greater meaning in clinical application in developing a drug for treating renal injury and renal failure.

The invention provides a traditional Chinese medicine used for treating renal failure and a preparation method thereof. The traditional Chinese medicine comprises following raw materials, by weight, 30 to 60 portions of raw astragali radix, 10 to 30 portions of raw rehmannia root, 10 to 30 portions of prepared rehmannia root, 10 to 30 portions of Chinese yam, 5 to 20 portions of angelica sinensis, 10 to 30 portions of radix pseudostellariae, 10 to 30 portions of eucommia ulmoides, 10 to 30 portions of loranthus parasiticus, 10 to 30 portions of polygala tenuifolia, 10 to 30 portions of poria cocos, 10 to 30 portions of rheum officinale, 5 to 20 portions of safflower carthamus, 4 to 8 portions of licorice, 10 to 30 portions of radix cyathulae, 10 to 30 portions of herba epimedii, 10 to 30 portions of radix dipsaci, 10 to 30 portions of rhizoma atractylodis macrocephalae, 10 to 30 portions of fried fructus aurantii and 30 to 60 portions of serissa serissoides. The results of more than 110 clinical experiments show that: effective rate of the traditional Chinese medicine in treatment of renal failure reaches to 82%, and 50% of the patients treated by using the traditional Chinese medicine are on the mend obviously. No toxic or side effect is caused by the traditional Chinese medicine, and the traditional Chinese medicine is capable of improving renal failure significantly. In addition, the traditional Chinese medicine is low in cost, is easy to prepare, can be popularized in the folk, and is capable of reducing medicine burden of patients.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.